Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen

Robert S. DiPaola, Robert E. Weiss, Kenneth B. Cummings, Feng Ming Kong, Randy L. Jirtle, Mitchell Anscher, Jose Gallo, Susan Goodin, Sharon Thompson, Zeeshan Rasheed, Joseph Aisner, Mary B. Todd

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF- β1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored.

Original languageEnglish (US)
Pages (from-to)1999-2004
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number11
StatePublished - Nov 1 1997

Fingerprint

Isotretinoin
Transforming Growth Factors
Prostate-Specific Antigen
NSC 153174
Interferons
Tretinoin
Biological Factors
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

DiPaola, R. S., Weiss, R. E., Cummings, K. B., Kong, F. M., Jirtle, R. L., Anscher, M., ... Todd, M. B. (1997). Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen. Clinical Cancer Research, 3(11), 1999-2004.

Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen. / DiPaola, Robert S.; Weiss, Robert E.; Cummings, Kenneth B.; Kong, Feng Ming; Jirtle, Randy L.; Anscher, Mitchell; Gallo, Jose; Goodin, Susan; Thompson, Sharon; Rasheed, Zeeshan; Aisner, Joseph; Todd, Mary B.

In: Clinical Cancer Research, Vol. 3, No. 11, 01.11.1997, p. 1999-2004.

Research output: Contribution to journalArticle

DiPaola, RS, Weiss, RE, Cummings, KB, Kong, FM, Jirtle, RL, Anscher, M, Gallo, J, Goodin, S, Thompson, S, Rasheed, Z, Aisner, J & Todd, MB 1997, 'Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen', Clinical Cancer Research, vol. 3, no. 11, pp. 1999-2004.
DiPaola RS, Weiss RE, Cummings KB, Kong FM, Jirtle RL, Anscher M et al. Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen. Clinical Cancer Research. 1997 Nov 1;3(11):1999-2004.
DiPaola, Robert S. ; Weiss, Robert E. ; Cummings, Kenneth B. ; Kong, Feng Ming ; Jirtle, Randy L. ; Anscher, Mitchell ; Gallo, Jose ; Goodin, Susan ; Thompson, Sharon ; Rasheed, Zeeshan ; Aisner, Joseph ; Todd, Mary B. / Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 11. pp. 1999-2004.
@article{c983dcb5a3c148b0acf9022bef3b5ae4,
title = "Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen",
abstract = "The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50{\%} decrease maintained for 1 month) or minimal (<50{\%} decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23{\%} (11-55{\%}) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151{\%} increase in TGF- β1 compared to 27{\%} in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored.",
author = "DiPaola, {Robert S.} and Weiss, {Robert E.} and Cummings, {Kenneth B.} and Kong, {Feng Ming} and Jirtle, {Randy L.} and Mitchell Anscher and Jose Gallo and Susan Goodin and Sharon Thompson and Zeeshan Rasheed and Joseph Aisner and Todd, {Mary B.}",
year = "1997",
month = "11",
day = "1",
language = "English (US)",
volume = "3",
pages = "1999--2004",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen

AU - DiPaola, Robert S.

AU - Weiss, Robert E.

AU - Cummings, Kenneth B.

AU - Kong, Feng Ming

AU - Jirtle, Randy L.

AU - Anscher, Mitchell

AU - Gallo, Jose

AU - Goodin, Susan

AU - Thompson, Sharon

AU - Rasheed, Zeeshan

AU - Aisner, Joseph

AU - Todd, Mary B.

PY - 1997/11/1

Y1 - 1997/11/1

N2 - The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF- β1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored.

AB - The objective of this study was to test the hypothesis that 13-cis- retinoic acid (CRA) and α-interferon (IFN-α) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor β1 (TGF-β1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-α administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-α was assessed by the measurement of plasma TGF- β1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-β1 levels increased with CRA and IFN-α therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF- β1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-α can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-β1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored.

UR - http://www.scopus.com/inward/record.url?scp=0030665439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030665439&partnerID=8YFLogxK

M3 - Article

C2 - 9815590

AN - SCOPUS:0030665439

VL - 3

SP - 1999

EP - 2004

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -